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Abstract
Background:  The pathophysiology behind spina bifida and other neural tube defects (NTDs) is
unclear. Folic acid is one variable, but other factors remain. Studies suggest that substances active
at the GABA receptor may produce NTDs. To test this hypothesis pregnant rats were exposed to
either the GABA a agonist muscimol (1, 2 or 4 mg/kg), the GABA a antagonist bicuculline (.5, 1, or
2 mg/kg), the GABA b agonist baclofen (15, 30, 60 mg/kg), or the GABA b antagonist
hydroxysaclofen (1, 3, or 5 mg/kg) during neural tube formation. Normal saline was used as a
control and valproic acid (600 mg/kg) as a positive control. The embryos were analyzed for the
presence of a spina bifida like NTD.
Results:  After drug administration the pregnancies were allowed to proceed to the 21st day of
gestation. Then embryos were removed and skeletons staining and cleared. Vertebral arch closure
was measured. Results indicate that the GABAa receptor agonist muscimol, the GABAa receptor
antagonist bicuculline, and the GABAb agonist baclofen produced NTDs characterized by widening
of the vertebral arch. Oppositely the GABAb antagonist hydroxysaclofen produced narrowing of
the vertebral arches.
Conclusions:  The findings indicate that GABA a or b ligands are capable of altering neural
formation. GABA may play a greater than appreciated role in neural tube formation and may be
important in NTDs. The narrowing of the vertebral arch produced by the GABA b antagonist
hydroxysalcofen suggests that GABA b receptor may play an undefined role in neural tube closure
that differs from the GABA a receptor.
Background
Neural tube defects (NTDs) are major malformations of
the central nervous system (CNS) due to a defect in the
covering of the CNS. They are among the most prevalent
of congenital malformations. NTDs are second only to
congenital heart defects as a cause of perinatal mortality
due to birth defect and range in incidence from 0.5 to 12
per 1000 live births, depending on the country, account-
ing for 400,000 births world-wide annually.
Factors that predispose individuals to NTDs are numer-
ous. While folic acid deficiency and altered folic acid me-
tabolism have received widespread attention, other
contributors are also important. Socio-economic status,
genetic factors, maternal illness and maternal drug expo-
sure are important contributors to the risk of NTDs.
Drug models of NTDs are valued because the drug's ac-
tion provides a possible explanation of the pathophysiol-
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ogy of NTDs. Valproic acid (VA) is a well-known
teratogen in both animals and humans, with a 5-fold oc-
currence of spina bifida (SB) in pregnant women ex-
posed to the drug [1]. The mechanism by which VA
produces SB is unknown but inhibition of folic acid me-
tabolism is one hypothesis [2,3]. Some investigators
have brought the folic acid hypothesis into question by
demonstrating that folic acid supplementation has no ef-
fect on VA exposed embryos in-vitro [4,5]. These studies
suggest that another mechanism may be responsible for
the production of SB by VA. Other possible mechanisms
include alteration of neuronal membrane conductance,
sodium channel blockade or altered neuronal calcium
metabolism [6]. VA is also known to allow GABA, the
chief inhibitory neurotransmitter of the CNS, to accumu-
late in tissues.
The role of GABA as a potential site for teratogen activity
for VA and other teratogens has been little explored. Pre-
liminary reports have linked ligands active at the GABA
receptor with SB or other NTDs, including benzodi-
azepines, alcohol, and zinc [7–11]. Preliminary work
from this laboratory has shown the GABAa receptor ago-
nist muscimol and the GABAb agonist baclofen produce
both SB and the Arnold-Chiari malformation, commonly
associated with SB [12–14]. VA appears to produce most
of its anticonvulsant effects by increasing levels of GABA
in the CNS, presumably by inhibiting the enzyme GABA-
transaminase (GABA-T). There is other evidence to sug-
gest that substances which alter the function of the
GABAergic system may contribute to the formation of
NTDs. Alcohol has been associated with NTDs [11] and is
known to enhance the functioning of GABA. Benzodi-
azepines (BDZs), which enhance the activity of the GABA
receptor, also enhance the teratogenic effects of VA in
humans [10]. Chlordiazepoxide, another BDZ, has been
shown to produce NTDs in the hamster [11].
Further support for the contention that VA may produce
NTDs by way of GABA activity include the following evi-
dence. One hypothesis of VAs mechanism of action holds
that it alters intracelluar pH. This may be the case as
GABA can increase intracellular proton levels by intensi-
fying bicarbonate ion conductance through a GABA-gat-
ed channel [15] which may act as a "developmental
handshake" and regulate neuronal differentiation [16].
The chloride channel, an integral part of the GABA a re-
ceptor, has been implicated in embryonic development
[17]. GABA receptors are first seen at the time the neural
tube formation [18]. Binding sites to GABA agonists and
antagonists and the expression of GABA receptor mR-
NAs are seen starting at 4 days of development and peak
at 10–15 days, corresponding to the time of neural tube
formation [19]. Many neurotransmitters, including
GABA, are growth factor candidates for the CNS [20–
22].
Based on the above information we have undertaken this
study to systematically examine the effects of GABA ago-
nists and antagonists at both the GABA a and b receptor
and the role they may play in SB. We used an established
model of SB in the rat to test the hypothesis using VA as
a known standard. This model of SB uses the width of the
vertebral arch as an indicator of neural tube closure.
While this model does not produce a specific SB lesion
the widening of the vertebral arch provides a model that
resembles human SB in terms of accompanying defects
[12–14,23] and response to folate and other drugs
[6,11,24,25] and meets the formal definition of a neural
tube defect: any defect in the covering of the central
nervous system.
We report here the effects of GABA a and b receptor ag-
onists and antagonists administered to rats at 10 days
gestation, the period of neural tube formation.
Results and Discussion
A total of 1156 embryos from 123 litters were examined.
Measurements from the embryos were averaged for each
litter and the litter was used as the unit of analysis. All
measurements were made in a blind manner. ANOVA re-
vealed a significant effect of drug treatment of the aver-
age vertebral arch distance (F(13, 109)=7.70, p < .0001).
The Bonferroni test was used for follow-up comparisons
and the comparisons to the normal saline group are giv-
en below and in Table 1 and in Figure 1 where the results
are presented graphically. Occasionally other defects
were noted in the embryos, chiefly fused ribs, these de-
fects were not appreciable and did not impact the verte-
bral arch analysis. There is no statistically significant
relationship between mean vertebral arch distance and
mean littler size.
Valproic Acid produced a significant widening of the ver-
tebral arch in a manner consistent with previous reports
(p < .0005) [6,24]
The GABAa agonist muscimol produced a significant
widening of the vertebral arch at all three doses tested (1,
2, 4 mg/kg) (p=.06 for 1 mg/kg, p < .05 for 2 & 4 mg/kg).
The GABAa antagonist bicuculline also widened verte-
bral arch distance at the 0.5 and 1 mg/kg doses (p < .05),
but not at the 2 mg/kg dose.
The GABAb agonist baclofen produced significant wid-
ening of the vertebral arch at 30 mg/kg (p < .05) but not
at 15 or 60 mg/kg. The GABAb antagonist hydroxysa-
clofen produced a significant narrowing of the vertebralBMC Pharmacology 2001, 1:2 http://www.biomedcentral.com/1471-2210/1/2
Figure 1
Effect of GABA receptor ligands on vertebral arch distance. Mean vertebral arch distance for drug groups. Error bars repre-
sent standard deviations. Exact probability differences from normal saline are given above error bars. See text for comments.
Table 1: Effect of GABA Ligands on Vertebral Arch Width
Drug Number Mean # Mean Arch S.D. Sig. (p=)
of Litters Embryos Width
per Litter (microns)
Normal Saline 15 8.67 71.5 16.4 N/A
Valproic Acid 15 7.20 90.5 19.5 .0005
Muscimol 1 3 10.67 89.3 11.9 .09
Muscimol 2 10 9.9 93.9 8.6 .0003
Muscimol 4 9 11.44 87.25 14.7 .01
Bicuculine 0.5 4 5.25 88.2 9.0 .04
Bicuculine 1 5 5.80 90.5 15.5 .01
Bicuculine 2 3 5.67 82.8 9.0 NS
Baclofen 15 14 8.64 73.6 17.3 NS
Baclofen 30 7 10.43 86.0 13.0 .03
Baclofen 60 10 10.10 75.5 14.6 NS
Hydroxysaclofen 1 10 9.80 61.5 9.6 .09
Hydroxysaclofen 3 9 5.00 50.8 16.2 .001
Hydroxysaclofen 5 9 8.56 59.15 3.15 .05BMC Pharmacology 2001, 1:2 http://www.biomedcentral.com/1471-2210/1/2
arch at all three doses tested (p=.09 for 1 mg/kg, p=.001
for 3 mg/kg and p=.05 for 5 mg/kg).
This study indicates that substances active at either the
GABA a or b receptors have teratogenic potential. The
most striking feature of the drug effects is the differential
effect of antagonizing the GABAb receptor with hydrox-
ysaclofen. While the GABAa agonist muscimol and an-
tagonist bicucullin widened the vertebral arch, as did the
GABAb agonist baclofen, the GABAb antagonist hydrox-
ysaclofen narrowed the vertebral arch. Narrowing of the
vertebral arch was unexpected but has been previously
reported. Previous work in this laboratory has demon-
strated narrowing of the vertebral arch when zinc is co-
administered with baclofen or muscimol [13]. It is un-
clear what the structural or functional consequence of
vertebral arch narrowing is. Work in this laboratory has
shown lags in neuromuscular development associated
with excessive zinc exposure during neural tube forma-
tion and, possibly, accompanying narrowing of the verte-
bral arches [26]. Another curious finding of this study is
that widening of the vertebral arch occurs with either the
GABAa agonist muscimol or the antagonist bicuculline.
In classic pharmacology it would be expected that the ef-
fects would be opposite. However, in this instance it may
be that any disruption of the normal function of the
GABAa receptor and its integral chloride channel result
in widening of the vertebral arch. On the other hand the
GABAb receptor is not directly linked to a chloride chan-
nel exerting its effect via second messenger systems. This
functional difference may allow for a classic agonist-an-
tagonist drug effect during neural tube formation.
One potential confound of this study is the role of devel-
opmental delays. Animals exposed to valproate and pre-
sumably suffering from widened vertebral arches can
show weight differences well into post-natal life. Howev-
er, behavioral differences persist even when weight dif-
ferences no longer exist [1]. However, we are unaware of
any studies directly examining the spinal columns of an-
imals well into post-natal life, therefore it is unclear if the
widening of the vertebral arch seen at 21 days persists.
Another limitation to this study is the small sample sizes
for some groups and the administration of drugs to only
one day. These results need to be replicated using larger
sample sizes and administering the drugs at other times
during gestation. It is possible that these drugs may dis-
rupt neural tube formation if given outside of the classic
time frame for neural tube formation.
GABA is a well-documented neurotrophic agent involved
in brain development [27–30]. Most of the work done on
the effects of GABA and neural development has been
done on embryos and embryonic tissue well past the neu-
ral tube stage [27,31,32]. However, there is evidence of
glutamic acid decarboxylase (GAD) and GABA receptor
expression about the time of neural tube formation [27].
Given that GABA is important to neural development,
and the early developmental time frame of the GABA sys-
tem, it is logical that agents active at the GABA receptor
(ethanol, BDZs) can have adverse consequences on CNS
development. Nearly all of the substances examined are
GABAa receptor ligands. GABAb receptor effects have
been little studied and the role of the GABAb receptor in
neural development is little known and should be more
thoroughly investigated.
Conclusions
GABA may play an important role in neural tube forma-
tion and the production of neural tube defects. Substanc-
es active at the GABA a or b receptor may be potentially
teratogenic. In particular, the findings indicate that
GABA a or b ligands are capable of altering neural forma-
tion. GABA may play a greater than appreciated role in
neural tube formation and may be important in neural
tube defects. The narrowing of the vertebral arch pro-
duced by the GABA b antagonist hydroxysalcofen sug-
gests that GABA b receptor may play an important, but
undefined role in neural tube closure that differs from
the GABA a receptor.
Materials and Methods
Female Long-Evans rats 120 days of age were housed
with ad-lib access to food and rat chow (Purina, Brent-
wood, MO) under 12:12 light:dark conditions. The fe-
males were mated with males of the same age and strain
overnight with the observation of a copulatory plug as ev-
idence of mating and counted as day 0 of pregnancy. The
females were then separated and housed singly. At 10
days of gestation the females were treated with one drug
as described below. Ten days of gestation corresponds
with neural tube formation in the rat. All drugs and
chemicals were obtained from Sigma Chemical, St, Lou-
is, MO. Doses were empirically determined with pilot
studies. This study was reviewed and approved by the In-
stitutional Animal Care and Use Committee of the Uni-
versity of Nebraska at Kearney.
Reference groups
Normal saline intraperitoneally (IP) 0.9 cc to establish
baseline.
Valproic acid subcutaneously (SC) 1200 mg/kg (600
mg/cc) in two divided doses over 8 hours. Previous stud-
ies have shown this dose and route to reliably produce SB
in the rat [24]. This group provided a positive control to
which the teratogenic activity of other substances could
be compared.BMC Pharmacology 2001, 1:2 http://www.biomedcentral.com/1471-2210/1/2
GABAa test groups
Muscimol IP at 1, 2, or 4 mg/kg (1 mg/cc). Muscimol is a
well-documented specific and potent GABAa agonist
[33].
Bicuculline methiodide IP at 0.5, 1 or 2 mg/kg (1 mg/cc).
Bicuculline is a well-documented specific and potent
GABAa antagonist [33].
GABAb test groups
Baclofen IP at 15, 30, or 60 mg/kg (9 mg/cc as aqueous
suspension). Baclofen is a well-documented and specific
GABAb agonist [34].
Hydroxysaclofen IP at 1, 3, or 5 mg/kg (1 mg/cc). Hy-
droxysaclofen is a well-documented specific and potent
GABAb antagonist [34].
Embryo studies
After injection gestation was allowed to otherwise
progress as normal. At 21 days gestation the females
were euthenized with chloroform, the abdomen opened
and the uterus and uterine contents removed. Fetuses
were removed and had their abdomens opened to allow
for the penetration of 10% 0.1 M phosphate buffered for-
malin in which they were immersed. After three days fix-
ation the fetuses were stained for bone and cartilage as
described previously [24]. Briefly, the fetuses were evis-
cerated and skinned. Cartilage was stained with alcian
blue followed by bone staining with alizarin red. The fe-
tuses were cleared in KOH and graded concentrations of
glycerol.
After clearing the fetuses were inspected with a dissect-
ing microscope and the width of the vertebral arch gap
was measured with an eyepiece micrometer from T-9 to
S-4. Previous work has shown that these vertebrae are
the most clearly visible and the most frequently effected
[6,24]. For the sake of clarity vertebral arch distances
from T-9 to S-4 were averaged for the each embryo.
For analysis vertebral arch distance was averaged for
each fetus and then for the litter. Data was analyzed with
Analysis of Variance with follow-up statistics (Bonferro-
ni test) using Statview 5.0 for the Macintosh.
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